The Food and Drug Administration Friday authorized the first molecular test to detect the SARS-CoV-2 virus in a nasal swab at home without a prescription. Cue Health expects by summer to daily produce more than 100,000 of the tests, authorized for use in patients age 2 and older.

The test has identified 96% of positive samples from people with symptoms and 100% of positive samples from people without symptoms. It includes a single-use test cartridge and nasal swab, reusable cartridge reader and mobile app, which in the future will allow users to report test results to public health authorities to monitor disease prevalence, FDA said.

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…